Kits detect mutations in DNA.
Share:
Press Release Summary:
Designed for universal primer fluorescent capillary electrophoresis, SURVEYOR® Kits detect mismatch mutations in DNA that has been PCR amplified using 2 fluorescent primers and digested with SURVEYOR Nuclease. SURVEYOR Nuclease identifies all base substitutions, insertions, and deletions and can detect multiple mutations in single fragment. Kits help scientists analyze genetic variation, even those present at very low levels such as somatic mutations linked to cancer.
Original Press Release:
Transgenomic Inc. Launches Next Generation SURVEYOR(R) Mutation Detection Kits for Fluorescent Capillary Electrophoresis
OMAHA, Neb., Jan. 15 /-- Transgenomic, Inc. (NASDAQ:TBIO) announced today that it is launching its next generation SURVEYOR Mutation Detection Kits for universal primer fluorescent capillary electrophoresis. The kits detect mismatch mutations in DNA that has been PCR amplified using two fluorescent primers and digested with SURVEYOR Nuclease. This then allows highly sensitive mutation detection on Applied Biosystems DNA sequencing instruments. It will be a key tool for scientists needing high-throughput analysis of genetic variation, even for those variations present at very low levels such as somatic mutations linked to cancer and its treatment.
Introduced by Transgenomic in 2004, SURVEYOR Nuclease is a proprietary mismatch-specific endonuclease that efficiently detects any mismatches in double-stranded DNA and cleaves at the site of DNA mutations. It identifies all base substitutions, insertions and deletions and can detect multiple mutations in a single fragment, in individual or even pooled PCR samples. SURVEYOR Nuclease's effectiveness in disease specific mutation discovery has been well documented in many peer-reviewed publications over the past two years.
In announcing the product launch, Craig Tuttle, Transgenomic, Inc. CEO, commented that, "We are excited to extend the SURVEYOR Mutation Detection Kit product line and provide such an important research tool to detect mutations that sequencing cannot find, or finds difficult to reveal. SURVEYOR also saves researchers time and money with its increased precision. SURVEYOR Endonuclease is an important expansion of Transgenomic's mutation detection product portfolio which is exemplified by our WAVE(R) System platforms and our emerging CLIA and GLP Clinical Reference Laboratory and Genomic Analysis and Research Services."
To find out more about SURVEYOR Nuclease, go to www.transgenomic.com and click on SURVEYOR Mutation Detection Products or contact Transgenomic at (888) 233-9283, +1 402 452 5400 or in Europe at +33 1 30 68 90 13.
About Transgenomic: A decade of discovery 1997 - 2007
Transgenomic is a global biotechnology company that provides unique systems, products, discovery and laboratory testing services to the academic and medical research, clinical and pharmaceutical markets for automated high sensitivity genetic variation and mutation analysis in the fields of pharmacogenomics and personalized medicine. This is accomplished through their offerings of Wave(TM) DHPLC systems, reagents, consumables and assay kits, automated cytogenetics systems and Transgenomic Discovery and CLIA Lab Services. To date there have been over 1,200 Wave systems installed in over 600 customer sites in over 35 countries and approximately 1,500 publications utilizing Transgenomic products or services. Transgenomic Discovery and Lab Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: www.transgenomic.com.
CONTACT: Dwight Muhlbradt of Transgenomic Inc., +1-402-452-5400
Web site: www.transgenomic.com/
